| Literature DB >> 34900352 |
Tirsit Kestela Zeleke1, Tilahun Yemanu Birhan2, Ousman Abubeker Abdela3.
Abstract
BACKGROUND: Kidney disease affects absorption, distribution, metabolism, and excretion of medicines and their metabolites. Therefore, when prescribing medicines for patients with kidney disease, dose adjustment is an accepted standard of practice.Entities:
Year: 2021 PMID: 34900352 PMCID: PMC8654552 DOI: 10.1155/2021/8238250
Source DB: PubMed Journal: Int J Nephrol
Sociodemographic characteristics of patients with renal impairment admitted to medical wards at Amhara region referral hospitals, Amhara Ethiopia, in 2020 (n = 424).
| Variables | Frequency | Percent |
|---|---|---|
| Age | ||
| <20 | 13 | 3.1 |
| 20–40 | 142 | 33.5 |
| 41–60 | 175 | 41.3 |
| >60 | 94 | 22.1 |
|
| ||
| Sex | ||
| Male | 227 | 53.5 |
| Female | 197 | 46.5 |
|
| ||
| Residence | ||
| Rural | 201 | 47.4 |
| Urban | 223 | 52.6 |
|
| ||
| Education | ||
| No formal education | 189 | 44.6 |
| Primary | 72 | 17.0 |
| Secondary | 49 | 11.6 |
| Higher | 114 | 26.8 |
|
| ||
| Occupation | ||
| Employed | 264 | 62.3 |
| Unemployed | 160 | 37.7 |
Clinical characteristics of patients with renal impairment admitted to medical wards at Amhara region referral hospitals, Amhara, Ethiopia, in 2020 (n = 424).
| Variables | Frequency | Percent |
|---|---|---|
| Reason for admission | ||
| AKI | 283 | 66.7 |
| CKD | 141 | 33.3 |
|
| ||
| Presence of comorbidities | ||
| Yes | 374 | 88.2 |
| No | 50 | 11.8 |
|
| ||
| Number of comorbidities | ||
| CHF | 99 | 23.3 |
| HTN | 158 | 37.3 |
| Stroke | 40 | 9.4 |
| IHD | 43 | 10.1 |
| DM | 124 | 29.2 |
| Pneumonia | 70 | 16.5 |
| UTI | 58 | 13.7 |
| AGN | 38 | 9.0 |
| SSI | 20 | 4.7 |
| Sepsis | 24 | 5.7 |
| Asthma | 58 | 13.7 |
| Anemia | 50 | 11.8 |
| Others | 15 | 3.5 |
|
| ||
| Stage in CKD patients | ||
| Stage 3 | 53 | 12.5 |
| Stage 4 | 37 | 8.7 |
| Stage 5 | 52 | 12.3 |
| Mean | SD | |
| Weight | 60.35 | 9.3 |
| Serum creatinine | 3.03 | 2.4 |
| GFR | 32.71 | 14.7 |
Preeclampsia, deep vein thrombosis (DVT), epilepsy, appendicitis, and meningitis.
Physicians' characteristics for medications prescribed in patients with renal impairment admitted to medical wards at Amhara region referral hospitals, Amhara Ethiopia, in 2020 (n = 424).
| Variables | Frequency | Percent |
|---|---|---|
| Specialty | ||
| General physician | 1334 | 84.4 |
| Internist | 247 | 15.6 |
|
| ||
| Length of work experience | ||
| ≤1 year | 190 | 12 |
| >2 years | 269 | 17 |
| ≥3 years | 1122 | 71 |
Frequency of medications prescription in patients with renal impairment admitted to medical wards at Amhara region referral hospitals, Amhara, Ethiopia, in 2020 (n = 424).
| Type of medications prescribed | Frequency of prescription |
|---|---|
| Enalapril | 167 |
| Cimetidine | 89 |
| Vancomycin | 87 |
| Spironolactone | 80 |
| Ciprofloxacin | 74 |
| Insulin | 65 |
| Hydrochlorothiazide | 58 |
| Ceftazidime | 55 |
| Digoxin | 53 |
| Metformin | 49 |
| Atenolol | 38 |
| Aspirin | 51 |
| Furosemide | 307 |
| Azithromycin | 13 |
| Ceftriaxone | 69 |
| Metronidazole | 25 |
| Amlodipine | 25 |
| Nifedipine | 59 |
| Metoprolol | 49 |
| Omeprazole | 33 |
| Atorvastatin | 46 |
| Warfarin | 22 |
| Others | 67 |
Others = heparin, ketoconazole, haloperidol, carvedilol, simvastatin, valproic acid, iron sulphate, propylthiouracil, amoxicillin, cobalamin, folic acid, beclomethasone puff, amitriptyline, hydralazine, diphenhydramine, paracetamol, carvedilol, and bisacodyl.
Appropriateness of medicines dosage adjustment in patients with renal impairment, who were admitted to medical wards at Amhara region referral hospitals, Ethiopia, in 2020 (n = 424).
| Type of medication | Frequency of prescription | Appropriately adjusted | Inappropriately adjusted | ||
|---|---|---|---|---|---|
| Frequency | Percent | Frequency | Percent | ||
| Cimetidine | 89 | 26 | 29.3 | 63 | 70.7 |
| Atenolol | 38 | 13 | 34.3 | 25 | 65.7 |
| Ciprofloxacin | 74 | 26 | 35.2 | 48 | 64.8 |
| Ceftazidime | 55 | 21 | 38.2 | 34 | 61.8 |
| Hydrochlorothiazide | 58 | 25 | 43.2 | 33 | 56.8 |
| Vancomycin | 87 | 42 | 48.3 | 45 | 51.7 |
| Digoxin | 53 | 27 | 51.0 | 26 | 49.0 |
| Spironolactone | 80 | 42 | 52.5 | 38 | 47.5 |
| Insulin | 65 | 36 | 55.4 | 29 | 44.6 |
| Enalapril | 167 | 105 | 62.9 | 62 | 37.1 |
| Metformin | 49 | 35 | 71.5 | 14 | 28.5 |
Factors associated with dose adjustment practice in patients with renal impairment admitted to medical wards at Amhara region referral hospitals, Amhara, Ethiopia, in 2020 (n = 424).
| Variable | Inappropriate dose adjustment | Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|---|---|
| Yes | No |
| COR | 95% CI |
| AOR | 95% CI | |
|
| ||||||||
| <20 | 5 (38.5) | 8 (61.5) | 1 | 1 | ||||
| 20–40 | 60 (42.3) | 82 (57.7) | 0.79 | 1.17 | (0.36–3.75) | 0.17 | 5.0 | (0.49–52.1) |
| 41–60 | 88 (50.3) | 87 (49.7) | 0.41 | 1.61 | (0.50–5.14) | 0.41 | 2.6 | (0.25–27.4) |
| >60 | 57(60.6) | 37 (39.4) | 0.13 | 2.46 | (0.74–8.11) | 0.88 | 0.8 | (0.76–9.2) |
|
| ||||||||
|
| ||||||||
| Male | 103 (45.4) | 124 (54.6) | 1 | 1 | ||||
| Female | 107 (54.3) | 90 (45.7) | 0.06 | 1.43 | (0.97–2.1) | 0.88 | 0.95 | (0.47–1.90) |
|
| ||||||||
|
| ||||||||
| Rural | 117 (58.2) | 84 (41.8) | 0.01 | 1.94 | (1.32–2.86) | 0.81 | 0.91 | (0.41–2.01) |
| Urban | 93 (41.7) | 130 (58.3) | 1 | 1 | ||||
|
| ||||||||
|
| ||||||||
| Employed | 109 (41.2) | 155 (58.8) | 1 | 1 | ||||
| Unemployed | 101 (63.1) | 59 (36.9) | <0.001 | 2.43 | (1.62–3.64) | 0.04 | 3.18 | (1.45–7.01) |
|
| ||||||||
|
| ||||||||
| No formal education | 119 (62.9) | 70 (37.1) | <0.001 | 3.68 | (2.25–6.03) | 0.91 | 2.39 | (0.86–6.61) |
| Primary | 39 (54.1) | 33 (45.9) | 0.02 | 2.56 | (1.39–4.70) | 0.61 | 1.30 | (0.46–3.61) |
| Secondary | 16 (32.6) | 33 (67.4) | 0.89 | 1.05 | (0.51–2.14) | 0.62 | 1.33 | (0.41–4.31) |
| Higher education | 36 (31.5) | 78 (68.5) | 1 | 1 | ||||
|
| ||||||||
|
| ||||||||
| Yes | 189 (50.5) | 185 (49.5) | 0.25 | 0.70 | (0.39–1.28) | 0.18 | 14.1 | (0.28–696.18) |
| No | 21 (42.0) | 29 (58.0) | 1 | 1 | ||||
|
| ||||||||
|
| ||||||||
| Stage 3 | 21 (39.6) | 32 (60.4) | 1 | |||||
| Stage 4 | 15 (40.5) | 22 (59.5) | 0.93 | 1.03 | (0.44–2.44) | |||
| Stage 5 | 26 (50) | 26 (50) | 0.28 | 1.52 | (0.70–3.301) | |||
|
| ||||||||
|
| ||||||||
| ≤1 year | 35 (68.6) | 16 (31.4) | 0.001 | 2.87 | (1.52–5.42) | 0.21 | 1.82 | (0.70–4.67) |
| 2 years | 45 (62.5) | 27 (37.5) | 0.01 | 2.19 | (1.29–3.7) | 0.73 | 1.14 | (0.52–2.50) |
| ≥3 years | 130 (43.1) | 171 (56.9) | 1 | 1 | ||||
|
| ||||||||
|
| ||||||||
| GP | 20 (29.4) | 48 (70.6) | <0.001 | 3.08 | (1.72–5.51) | 0.21 | 1.75 | (0.72–4.26) |
| Internist | 190 (53.3) | 166 (46.7) | 1 | 1 | ||||
| Weight | 61.4 (±9.2) | 59.3 (±9.24) | 0.02 | 1.02 | (1.00–1.04) | 0.22 | 0.97 | (0.94–1.01) |
| Number of comorbidities | 1.58 (±0.85) | 2.84 (±1.0) | <0.001 | 3.99 | (2.99–5.31) | 0.01 | 1.65 | (1.09–2.48) |
| SrCr | 3.02 (±2.30) | 3.03 (±2.42) | 0.96 | 0.99 | (0.92–1.08) | |||
| GFR | 31.67 (±14.30) | 33.74 (±15.02) | 0.14 | 0.99 | (0.97–1.00) | 0.58 | 0.9 | (0.97–1.01) |
| Number of medications | 5.04 (±1.36) | 3.02 (±1.18) | <0.001 | 3.29 | (2.63–4.10) | <0.001 | 3.20 | (2.28–4.49) |
p < 0.05.